Dr John Marshall previews the upcoming 2015 Ruesch Symposium, in which policy makers, insurers, regulators, researchers, and patients debate about what therapies are worth pursuing in GI cancer.

Dr Peter Yellowlees talks about a randomized controlled trial studying the effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant medication.

Dr Paul Auwaerter shares good news from IDWeek 2015, including updates on anti-infectives--6 new weapons in the battle against resistant organisms.

How to test, how to treat, and what not to use anymore--and yes, there is an app.

Patient deaths have been reported when healthcare providers confused tPA and TNK. Follow these suggestions to prevent any further mishaps.

Dr Andrew Kaunitz summarizes the issues you need to be aware of before prescribing flibanserin (Addyi).

Eric Topol interviews Eric Schadt on how he turned math into medicine, and his need for speed both at and outside of work.

Dr Paget discusses the potential impact of biosimilars in rheumatology and some of the unanswered questions about their use.

CDC director Tom Frieden reports that heroin is cheap, potent, and available, all of the prerequisites for a widespread epidemic of abuse.

Research trials of psychedelic drugs were truncated by the politics of the 1960s. Dr Lieberman explains why we need to begin studying them again, before public opinion gets ahead of what we know.